Search research articles
Contact Us
Filters
Showing results (31-40 of 58) with videos related to
Page
of 6
Sort By:
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
August 30, 2016
Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study
Erdinc Nayir, Ozgur Tanriverdi, Yusuf Karakas, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
May 11, 2018
Adding taxane to platin-5-fluorouracil combination does not improve survival rate in patients ≥ 65 years of age with advanced gastric cancer: A retrospective-multicenter study
Meral Gunaldi, Fatih Kose, Nebi Serkan Demirci, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
April 4, 2019
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Serkan Degirmencioglu, Ozgur Tanriverdi, Serkan Menekse, et al.
Experimental Hematology & Oncology
|
June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer
Taha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Neoplasma
|
January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study
Elvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Current Oncology (Toronto, Ont.)
|
September 27, 2024
Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 58) with videos related to
Sort By:
Page
of 6
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
August 30, 2016
Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study
Erdinc Nayir, Ozgur Tanriverdi, Yusuf Karakas, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
May 11, 2018
Adding taxane to platin-5-fluorouracil combination does not improve survival rate in patients ≥ 65 years of age with advanced gastric cancer: A retrospective-multicenter study
Meral Gunaldi, Fatih Kose, Nebi Serkan Demirci, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
April 4, 2019
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Serkan Degirmencioglu, Ozgur Tanriverdi, Serkan Menekse, et al.
Experimental Hematology & Oncology
|
June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer
Taha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Neoplasma
|
January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study
Elvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Current Oncology (Toronto, Ont.)
|
September 27, 2024
Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, et al.
Page
of 6